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There is mounting evidence showing that mitochondrial damage plays an important role in Alzheimer disease. Increased oxygen
species generation and deficient mitochondrial dynamic balance have been suggested to be the reason as well as the consequence
of Alzheimer-related pathology. Mitochondrial damage has been related to amyloid-beta or tau pathology or to the presence of
specific presenilin-1 mutations. The contribution of these factors to mitochondrial dysfunction is reviewed in this paper. Due
to the relevance of mitochondrial alterations in Alzheimer disease, recent works have suggested the therapeutic potential of
mitochondrial-targeted antioxidant. On the other hand, autophagy has been demonstrated to play a fundamental role inAlzheimer-
related protein stress, and increasing data shows that this pathway is altered in the disease. Moreover, mitochondrial alterations
have been related to an insufficient clearance of dysfunctional mitochondria by autophagy. Consequently, different approaches
for the removal of damaged mitochondria or to decrease the related oxidative stress in Alzheimer disease have been described.
To understand the role of mitochondrial function in Alzheimer disease it is necessary to generate human cellular models which
involve living neurons. We have summarized the novel protocols for the generation of neurons by reprogramming or direct
transdifferentiation, which offer useful tools to achieve this result.
1. Introduction
Alzheimer disease (AD) is characterized by the presence of
two aberrant structures in the brain of the patients, senile
plaques and neurofibrillary tangles, together with marked
neuronal death [1]. Senile plaques are filamentous aggregates
of amyloid-beta peptide (A𝛽) [2], whereas the main compo-
nent of neurofibrillary tangles is the microtubule-associated
protein tau [3]. This picture of the patients’ brain showing
plaques and tangles can be found at the end of the dis-
ease, usually at autopsy; however, using imaging techniques
like positron emission tomography these aggregates can be
detected in vivo in Alzheimer’s patients by using compounds
like the Pittsburg compound B for amyloid [4] or 18F-THK23
for Tau aggregates [5].
It is suggested that Alzheimer disease is a silent neu-
rodegeneration where neuronal damage occurs before the
diagnosis of the disease. Thus, plaques and tangles may
appear before the onset of the disease symptoms [6]. On the
other hand, mitochondrial dysfunction is one of the earliest
and most prominent features in vulnerable neurons in the
brain ofADpatients [7] and likely in other neurodegenerative
disorders [8].
There are at least two types of Alzheimer disease: familial
Alzheimer disease (FAD) and sporadic Alzheimer disease
(SAD). In FAD, the causes of the disease are the presence of
specific mutations in at least one of the three genes identified
as amyloid precursor protein (APP) and presenilin-1 and -2
(ps-1 and ps-2) [9]. However, little is known about the cause
of the onset of SAD. It is known that the main risk for AD
is aging related to oxidative damage [10]. It has been found
that oxidative damage may facilitate the expression of beta-
secretase (BACE1), a protein involved in the generation of
A𝛽 [11, 12]. Moreover, it has been shown that oxidative stress
induces a pathogenic PS1 conformational change in neurons
in vitro, increasing A𝛽42/40 ratio [13]. In FAD, increased
A𝛽may result in mitochondrial dysfunction and augmented
ROS levels [14]. In SAD, the reverse has been suggested.
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Mitochondria-derived reactive oxygen species result in an
enhanced amyloid-beta formation [15] and the A𝛽 increase
may lead to further mitochondrial dysfunction, resulting in
even higher ROS levels [16]. Then, the cycle repeats and
degeneration increases. Also, oxidative stress may facilitate
tau phosphorylation at some of the sites found to bemodified
in AD patients [17, 18]. On the other hand, tau accumulation
causes mitochondrial distribution deficits in a mouse model
for AD [19].
2. Mitochondrial Damage in AD
2.1. Oxidative Stress and Energy Production. Oxidative stress
is a primary event in the development of AD [10]. This
oxidative stress may be due to the presence of dysfunctional
mitochondria resulting in generation of reactive oxygen
species [20]. Mitochondria generate cell energy as electrons
flow through mitochondrial complex I to IV of the electron
transport chain, from donors with lower redox potential to
acceptors with higher redox potential. The final acceptor is
oxygen that is reduced to water and the generated energy
drives the phosphorylation of ADP to ATP by the mitochon-
drial complex V (or ATP-synthase) (Figure 1). Although the
transport of the electrons through mitochondrial complexes
is an efficient process, some reactive oxygen species (ROS)
may be produced. Dysfunctionalmitochondria generate high
levels of ROS that may be toxic for cells with a long life span
and a deficiency in antioxidant defenses, such as neurons
[21]. Additionally, mitochondria are at the same time a target
of ROS causing the oxidation of their components such
as mtDNA, lipids, and proteins increasing mitochondrial
deterioration. Mitochondrial dysfunction is one of the ear-
liest and most prominent features of AD [22, 23]. In fact,
a decreased expression of either nuclear or mitochondrial
genes of the oxidative phosphorylation in the neocortex of
AD patients has been shown to correlate with progressive
reductions in brain glucosemetabolism that can be visualized
by positron emission tomography [24, 25]. Testingmitochon-
drial function in a triple transgenic mouse model for AD,
a clear deregulation of oxidative phosphorylation proteins
was found [26]. Deregulation of complex I was related to
tau toxicity as found in other animal models [27] whereas
deregulation of complex IV has been described to be A𝛽
dependent [28, 29] (Figure 1).
Alterations of several enzymes involved in the tri-
carboxylic acid cycle such as pyruvate dehydrogenase
and 𝛼-ketoglutarate dehydrogenase have been reported in
Alzheimer disease (Figure 1). Postmortem brains showed a
reduction of pyruvate dehydrogenase, ATP-citrate lyase, and
acetoacetyl-CoA thiolase correlating with decreased produc-
tion of acetylcoenzyme A and the subsequent cholinergic
defects observed in these patients [30]. Reduced activity of
𝛼-ketoglutarate dehydrogenase was also observed in brain
tissue as well as in peripheral cells from AD patients [31, 32].
Additionally in AD brain, there is a loss of 𝛼-ketoglutarate-
enriched cells, therefore causing the degeneration of 𝛼-
ketoglutarate-enriched areas (cortical layers II and IV) which
are the ones that are selectively degenerated in AD [33].
On the other hand, products of the toxic action of ROS,
like hydroxynonenal (HNE), or the presence of quinones
(like coenzyme Qo) may facilitate the self-assembly of Tau
protein into fibrillar polymers similar to those paired helical
filaments present in the brain of AD patients [34]. These
findings suggest another possible link between oxidative
stress, neuronal dysfunction, and AD.
It is possible that mitochondrial dysfunction in AD
patients not only takes place in the central nervous system
but also in cells from peripheral tissues. Increased oxidative
stress levels and reduced antioxidant defenses have been
observed in AD fibroblasts [35]. Regarding this, it has been
described that lipoic acid and N-acetylcysteine may decrease
the mitochondrial-related oxidative stress in Alzheimer dis-
ease patients [36].
2.2. Mitochondrial Dynamics Alteration. Mitochondria are
highly dynamic organelles, ranging from giant tubular net-
works to small round entities through rapid and reversible
fission and fusion processes. Mitochondria failure may arise
from a deficient dynamic balance of mitochondrial fission
and fusion that, in AD, is greatly shifted toward fission and
it may result in the presence of dysfunctional mitochondria
in damaged neurons [37].
The delicate balance of fission and fusion is regu-
lated by several mitochondrial proteins (Figure 2). Fission
requires several outer mitochondrial membrane (OMM)
proteins such as the GTPase dynamin-like protein 1 (DLP1,
also known as dynamin-related protein, Drp1) that is
recruited from the cytosol to the OMM for fission [38].
This process depends on its GTPase activity as well as
on posttranslational modifications such as phosphorylation,
S-nitrosylation, sumoylation, and ubiquitination [39–42].
Other OMMproteins involved in fission are Fis1, which plays
a regulatory role, andmitochondrial fission factor,Mff, which
is fundamental for the mitochondrial recruitment of DLP1
[43]. On the other hand, mitochondria fusion depends on
otherGTPases such asmitofusin 1 and 2, responsible for outer
membrane fusion, and optic atrophy, Opa1, that carries out
fusion of the innermembrane and is also important for cristae
formation and mtDNA inheritance [44]. The involvement
of mitochondrial elongation factor, MIEF1, in mitochondrial
fusion in vertebrates has recently been described. This factor
recruits and inactivates DLP1 executing a negative effect on
fission and actively promotes fusion in a manner distinct
from mitofusins [45].
Mitochondrial dynamics are critical for the maintenance
of mitochondrial integrity and functions including energy
metabolism, ROS generation, and apoptosis regulation [7].
Fusion permits the proper distribution of mitochondrial
components such as lipids membranes, oxidative phospho-
rylation complexes, and mtDNA. Moreover, fusion is impor-
tant in maintaining the proper mitochondrial ultrastructure
and elongation is a mechanism for mitochondria to escape
autophagy-mediated destruction. On the other hand, fission
permits the recycling of irreversibly damaged mitochondria
by mitophagy and plays an important role in the proper
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Figure 1:AD-related alterations of mitochondrial respiratory chain and tricarboxylic acid cycle. Scheme of alterations in protein levels found in
Alzheimer disease brains as well as the targets of amyloid-𝛽 (A𝛽) and phosphorylated Tau (pTau). Oxidative phosphorylation complexes are
labeled as CI to CIV. PDH: pyruvate dehydrogenase, 𝛼-KG: 𝛼-ketoglutarate, 𝛼-KGDH: 𝛼-ketoglutarate dehydrogenase, OAA: oxaloacetate.
assembly of mitochondrial electron transport chain com-
plexes. A proper balance of fusion and fission proteins is
fundamental for the correct distribution of the mitochondria
in the cell [44]. This is particularly important for neurons
that may have very long axons and also for the function of
synapses, which are subcellular regions with high metabolic
requirement [46].
Possible dysfunction of mitochondrial dynamics proteins
has been tested in models for neurodegenerative disorders
[47, 48], Alzheimer disease being one of them [49]. In
fact, abnormal mitochondrial dynamics and synaptic degen-
eration are considered early events in Alzheimer Disease
(extensively discussed in Reddy et al. [50]). Mitochondrial
dynamics alteration has been found either in neurons or
fibroblasts in AD patients and models [7]. Mitochondria
distribution has also been found altered in both cell types
characterized by their accumulation into perinuclear areas.
However, while neurons exhibit increased fragmentation,
fibroblasts show elongated and highly interconnected mito-
chondrial network [47]. Vulnerable neurons in AD brain
exhibit significant reduction in mitochondrial length and
increased width with a significant increased overall size
consistent with unopposed fission suggesting alterations of
mitochondrial dynamics [48]. In agreement with these find-
ings, an abnormal distribution of mitochondria was found
in pyramidal neurons of AD-affected individuals where
mitochondria were redistributed away from axons in the
pyramidal neurons [51]. Accordingly, levels of fusion proteins
OPA1, Mfn1, and Mfn2 were significantly reduced whereas
levels of Fis1 were significantly increased in AD (Figure 2). In
the case of the fission protein DLP1, while some authors have
described a reduction in neurons [47, 52] and fibroblasts of
sporadic patients [47], others have shown an increase [53].
These differences can be explained because the major pool of
DLP1 is cytosolic and its recruitment onmitochondrialmem-
brane to mediate fission events depends on posttranslational
modifications [7] (Figure 2). In this sense, higher DLP1 levels
in mitochondrial fraction [51] as well as increased Ser616
phosphorylation and S-nitrosylation in AD brains [40] have
been described. Primary hippocampal neurons treated with
A𝛽-derived diffusible ligands (ADDLs) demonstrated short-
ened mitochondria in neurons and alteration of fission and
fusion proteins [51]. Moreover, time-lapse recordings in these
neurons showed impairment of both, fission and fusion
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processes, with fusion process being more severely affected
[51]. Recent evidence has shown an abnormal interaction of
A𝛽 monomers and oligomers with DLP1 that increases with
the progression of the disease suggesting a possible cause of
abnormalmitochondrial dynamics and synaptic damage [53].
On the other hand, the expression of AD-causing Swedish
APP mutation in M17 cells also induced shorter and fatter
mitochondria, with a slight but significant increase in size,
but a decrease in the total mitochondrial number while
the number of damaged mitochondria was increased [48].
Similar observations have been found in transgenic mice
(Tg2574) harboring the APP Swedish mutation [54].
Abnormal mitochondrial morphology has been found in
fibroblasts from sporadic AD patients, where they become
significantly elongated and form a highly connected network
[47]. This discrepancy in mitochondrial morphology may
be due to differences in the expression pattern of pro-
teins involved in dynamics, showing decreased DLP1 and
unchangedOPA1. Similar differences between fibroblasts and
neurons have been also found in Parkinson’s disease [7].
Mitochondrial mobility has also been altered in AD
causing a mitochondrial reduction in neurites [7] (Figure 2).
A𝛽 induces a reduction in motile mitochondria [55] and
ADDL impairs anterograde and retrograde axonal transport
of mitochondria in hippocampal neurons [56]. Primary
neurons from Tg2576 APP transgenic mice showed a spe-
cific impairment of anterograde mitochondrial transport.
These results suggest that mitochondrial fission/fusion and
mitochondrial transport can be coupled. In fact, it has been
demonstrated that Mfn2 interacts withMiro andMilton, two
adaptor proteins involved in the regulation of mitochondrial
transport [57], although further work is necessary to clarify
this relationship.
The alteration in mitochondrial dynamics leads to severe
consequences in the cell such as structural changes in
the cristae formation and assembly of electron transport
complex compromising bioenergetics and causing calcium
dyshomeostasis, increased oxidative stress, mitochondrial
DNA damage, and synaptic dysfunction (reviewed in [7]).
3. Relationship between Mitochondrial
Dysfunction and AD-Related Pathology
3.1. Amyloid Beta. In FAD, an increase in the level of A𝛽
may result in oxidative damage [22, 58, 59]. APP and A𝛽
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accumulate in mitochondrial membranes causing structural
and functional damage (reviewed in [60]). Nonglycosylated
full-length and C-terminal truncated APP has been found to
accumulate in the protein import channels of mitochondria
of human AD brains [61] (Figure 2). APP forms stable
complexes with the translocase of the outer mitochondrial
membrane 40 (TOM40) import channel and the translocase
of the inner mitochondrial membrane 23 (TIM23) inhibiting
the entry of nuclear-encoded cytochrome 𝑐 oxidase subunits
IV and Vb proteins, which was associated with decreased
cytochrome 𝑐 oxidase activity and increased ROS production.
Additionally, an interaction has been discovered between
A𝛽 and phosphorylated Tau with voltage-dependent anion
channel 1 (VDAC1) in the brains of AD patients and from
APP, APP/PS1, and 3XTg AD mice which may block the
mitochondrial pores leading to mitochondrial dysfunction
[62].
Amyloid-beta interacts with the mitochondrial protein
ABAD (A𝛽-binding alcohol dehydrogenase) which is upreg-
ulated in the temporal lobe of AD patients as well as in
A𝛽PP transgenic mice [63] (Figure 2).This complex prevents
the binding of nicotinamide adenine dinucleotide NAD+ to
ABAD, thereby changing mitochondrial membrane perme-
ability and reducing the activities of respiratory enzymes
causing elevated ROS.
Moreover, it has been suggested that the oxidative stress
induced by A𝛽 may oxidize and inactivate presequence pro-
tease, PreP, one of the proteins involved in A𝛽 degradation in
the mitochondria thus increasing A𝛽 concentration in mito-
chondrial matrix and its pathologic effects [64] (Figure 2).
Amyloid-beta has been also involved in alterations of
mitochondrial dynamics. In fact, the overexpression of
human APP Swedish double mutation in neuroblastoma cell
lines induces a higher percentage of highly fragmented and
slower mitochondria correlating with an alteration of the
levels of the proteins involved in mitochondrial dynamics
such as increased fission protein Fis-1 and reduced levels
of fusion proteins like OPA1 and DLP-1 [48]. In agreement
with these in vitro findings, an abnormal distribution of
mitochondria was also found in pyramidal neurons of AD-
affected individuals.
Additionally, A𝛽 enhances nitrosative stress-inducing s-
nitrosylation of DLP1, which favorsmitochondrial fission fol-
lowed by mitochondrial depletion from axons and dendrites
and subsequently synaptic loss [40] (Figure 2).
Mitochondrial A𝛽 may also interact with cyclophilin D,
an integral part of the mitochondrial permeability transition
pore (mPTP), which potentiates free radical production,
causes synaptic failure, and promotes the opening of the
mPTP leading to apoptosis [65] (Figure 2).
On the other hand, A𝛽 accumulation could result in
cytoskeletal aberrations [66] (Figure 2). A𝛽 oligomers inter-
act with integrins leading to improper control of focal
adhesion assembly and signaling, therefore causing the dys-
regulation of cofilin, which is involved in the regulation of
actin dynamics.The inhibition of actin dynamics is associated
with increased ROS production and reduced mitochondrial
potential. Moreover, cofilin in response to oxidative stress
translocates to the mitochondria where it induces swelling, a
drop in mitochondrial membrane potential, and cytochrome
𝑐 release promoting the opening of mPTP and apoptosis.
3.2. Presenilin. Presenilins 1 and 2 are multitransmembrane
proteins that associate with nicastrin, APH-1, and PEN-2,
form high-molecular 𝛾-secretase complex, and are involved
in A𝛽 production byintramembrane cleavage of APP. Ps-1
gene mutations are the most prevalent in FAD, but besides
the generation of A𝛽, little is known about its implication
in mitochondrial dysfunction and oxidative damage. It has
been demonstrated that presenilin-1 [67] and presenilin-2
are also located in mitochondria as part of the 𝛾-secretase
complex [68]. Noteworthy, presenilin mutations have been
shown to sensitize cells to apoptosis by mechanisms sug-
gested to involve impaired mitochondrial function and Ps-
2/𝛾-secretase activity can modify mitochondrial membrane
potential [69]. Moreover, ps-2 KO mouse embryonic fibrob-
lasts exhibit lower basal respiratory rate. On the other hand,
in at least two transgenic mouse models expressing human
tau with AD mutations at presenilin-1, PS1M146L [70] and
PS1A246E [71], the existence of mitochondrial abnormalities
prior to cognitive deficits has been described. Also, in the case
of PS1M146L mice, it was found that the mutation increases
mitochondria ROS formation and oxidative damage. Finally,
it has been recently shown that presenilins and 𝛾-secretase
activities are concentrated in a specialized subcompartment
of the endoplasmic reticulum (ER) that is physically and bio-
chemically connected to mitochondria, called mitochondria-
associated ER membranes (MAM) which are involved in
mitochondrial function and dynamics, among others [72, 73].
Either in presenilin KO mice or fibroblasts from FAD and
SAD patients, MAM function is increased correlating with
a significantly increased area of apposition between ER and
mitochondria.
3.3. Tau. Tau is involved in the axonal transport of organelles
such as mitochondria [74]. Hyperphosphorylated Tau may
block the transport of mitochondria leading to energy depri-
vation and oxidative stress at the synapse as well as to
neurodegeneration [75] (Figure 2). Analysis of brain proteins
from P301L mutant human tau transgenic mice revealed
deregulation of mitochondrial respiratory chain complex
components such as complex V and reduced complex I
activity as well as an impairedmitochondrial respiration with
the subsequent ROS accumulation with aging [27] (Figure 1).
Accordingly, the overexpression of P301L tau mutation in
human neuroblastoma cells has been shown to induce sub-
stantial complex I deficit accompanied by decreased ATP
levels and increased susceptibility to oxidative stress [76].
This was paralleled by pronounced changes in mitochondrial
morphology, decreased fusion and fission rates accompanied
by reduced expression of OPA-1 and DLP-1. In contrast,
the overexpression of wt tau exhibited protective effects on
mitochondrial function and dynamics including enhanced
complex I activity. Moreover, an abnormal interaction of
hyperphosphorylated Tau and mitochondrial fission protein
DLP-1 has been described suggesting a relationship with
mitochondrial dynamics alteration [77] (Figure 2). Other
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researchers have found that the expression of human tau
mutations in both Drosophila (R406W) and mouse neurons
(P301L) results in elongation of mitochondria, which is
accompanied by mitochondrial dysfunction and cell cycle-
mediated cell death [78]. We have previously mentioned an
interaction of phospho-Tau and VDAC1 that may in turn
block the mitochondrial pores leading to mitochondrial dys-
function [62] (Figure 2). On the other hand, increased oxida-
tive stress has been shown to cause Tau hyperphosphoryla-
tion in a superoxide dismutase 2 knockoutmousemodel [79].
Furthermore, the inhibition of complex I with annonacin led
to a redistribution of Tau from the axons to the cell body
which correlates with a retrograde transport of mitochondria
and finally to cell death [80]. Lastly, the downregulation of
the proteins involved in the axonal transport ofmitochondria
such as Miro and Milton in Drosophila has shown loss of
axonal mitochondria that promotes Tau phosphorylation in
Ser262 via partitioning defective-1 (Drosophila homolog of
mammalian microtubule affinity-regulating kinase) causing
late-onset neurodegeneration in the fly [81].
4. The Use of Mitochondria-Targeted
Antioxidants in AD
Since, as previously indicated, mitochondrial dysfunction
and oxidative stress may play a role in the development of
AD, many efforts have been proposed to demonstrate the
therapeutic potential of antioxidants in this disease. Different
components such as vitamin E [82], curcumin [83], Gingo
biloba [84], and melatonin [85] have demonstrated their
potential to reduce A𝛽 levels and improve mitochondrial
function and cognitive behavior in animal models of AD.
However, clinical trials using these antioxidants or others,
such as huperzine A, have shown only modest or no effect
in cognitive function. The modest effect may be related
to unsuccessful cross of the blood-brain barrier, not well-
thought-out experimental design of the clinical trials, or the
late stage of patients involved [50].
To improve this poor result many efforts have been
done to develop mitochondria-targeted antioxidants, such
as triphenylphosphonium-based antioxidants (MitoQ,
MitoVitE, Mito-𝛼-lipoic acid, MitoPBN) [86], cell-
permeable small peptide-based molecules (SS31, SS02,
SS19, and SS20) [87], and choline esters of glutathione and
N-acetyl-l-cysteine [88]. The first group results from the
combination of lipophilic triphenylphosphonium cation
with ubiquinol, 𝛼-tocopherol, 𝛼-lipoic acid, and 𝛼-phenyl-
N-tert-butylnitrone, respectively. Due to their positive
charge they are accumulated several hundredfold within
mitochondria driven by the membrane potential, enhancing
the protection of mitochondria from oxidative damage [86].
MitoQ accumulates in mitochondria driving the conversion
of H
2
O
2
to H
2
O and O
2
, reducing the toxic insult of free
radicals.
Szeto-Schiller or SS peptides are a serial of small cell-
permeable antioxidant peptides which have a sequence motif
that allows them to target mitochondria [87]. They scavenge
H
2
O
2
and ONOO– and inhibit lipid peroxidation. Their
antioxidant activity is attributed to the tyrosine or dimethyl-
tyrosine (Dmt) residue. Dmt has demonstrated to be more
effective than tyrosine in scavenging of ROS. SS31 (H-D-Arg-
Dmt-Lys-Phe-NH2) has demonstrated its efficacy in rodent
models of different diseases.
The antioxidant effect of MitoQ and SS31 has been tested
in vitro in mouse cell models of AD [89]. Both components
were able to prevent the effects ofA𝛽 inmouse neuroblastoma
(N2a) cells, such as increased expression of mitochondrial
fission genes, decreased expression of fusion genes, peroxire-
doxins, and endogenous cytoprotective antioxidant enzymes,
and, increased number of intact mitochondria and neurite
outgrowth. Additionally, in neurons from a mouse model of
AD (A𝛽 precursor protein transgenic mouse, Tg2576 line)
incubated with A𝛽, MitoQ and SS31 achieved an increase in
neurite outgrowth and a decrease in cyclophilinD expression.
Posterior work using primary neurons from Tg2576 mice
[54] confirmed the capacity of SS31 to mitigate the effects
of oligomeric A𝛽, such as decreased anterograde mitochon-
drial movement, increased mitochondrial fission, decreased
fusion and structurally damaged mitochondria, abnormal
mitochondrial and synaptic proteins, defective mitochon-
drial function, and apoptotic neuronal death. SS31 was able
to restore mitochondrial transport and synaptic viability
and decreased the percentage of defective mitochondria,
demonstrating its protective effect from A𝛽 toxicity.
Moreover, MitoQ has been shown to prevent cognitive
decline in 3xTg-AD mice as well as early neuropathology,
such as oxidative stress, A𝛽 accumulation, astrogliosis, synap-
tic loss, and caspase activation [90].
Another example of mitochondria-targeted antioxidants
could be the compound SKQ1 (plastoquinonyl decyltriph-
enylphosphonium), a membrane-penetrating cation that is
specifically accumulated in the inner mitochondrial mem-
brane [91]. SKQ1 lowers the rate of ROS formation in the
respiratory chain due to mild uncoupling. SKQ1 reversed the
appearance of a typical behavioral trait of aging in rats [92].
Further evidence suggesting the therapeutic capacity of
mitochondria-targeted antioxidants was recently obtained
from the in vivo studies using APP transgenic mice that
carried the human mitochondria-targeted catalase (MCAT)
gene [93]. These mice lived 5 months longer than did APP
mice. Their brain sections showed a reduction in the levels
of full-length APP, C-terminal fragment 99, BACE1, A𝛽
levels (40 and 42), A𝛽 deposits, and oxidative DNA damage
relative to the brain sections from theAPPmice. Additionally,
significant increased levels of soluble APP𝛼 and C-terminal
fragment 83 were found in the MCAT/APP mice, suggesting
that oxidative stress plays a primary role in AD etiopathology.
All these findings indicate that mitochondria-targeted
molecules may be an effective therapeutic approach to treat
patients with AD.
5. Removal of Defective Mitochondria
Autophagy is a normal cellular recycling process that involves
degradation of intracellular components including proteins,
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protein complexes, and organelles through lysosomal degra-
dation.Mitochondrial function is regulated by autophagy in a
process namedmitophagy, inwhich dysfunctionalmitochon-
dria are recycled by engulfment into autophagosomes that
then fuse with lysosomes for their content degradation. The
segregation of damagedmitochondria depends on fission and
fusion events that, as we have previously discussed, are altered
in AD. Although increased mitochondrial autophagy in AD
has been described [94], further studies will be necessary to
clarify if this is a protective process because they may not be
properly recycled by fusion with lysosomes or it may not be
selective for damaged mitochondria.
One of the mechanisms described for the regulation
of mitochondrial recycling by autophagy involves the E3
ubiquitin ligase Parkin. After mitochondrial damage, PTEN-
induced kinase 1 (PINK1) is stabilized in mitochondria
inducing the recruitment of Parkin [95]. Parkin-mediated
ubiquitination recruits autophagy adapter proteins, such as
p62, which interacts with LC3 mediating the cargo engulf-
ment into autophagosomes. Parkin ubiquitinates several
mitochondrial proteins, such as VDAC1 [96] and mitofusins
that may be involved in the segregation of damaged mito-
chondria via an inhibition of mitochondrial fusion events
[97]. Therefore the alterations described in mitochondrial
dynamics-related proteins and autophagy in AD may affect
the mitophagy increasing mitochondrial damage and ROS
accumulation.
In AD, A𝛽, and Tau aggregation has been associated
withmitochondrial damage, oxidative stress, and cytoskeletal
alteration of neurons. Autophagy plays a fundamental role in
neuronal function and is intensively involved in AD-related
protein aggregation [98]. Indeed, it has been demonstrated
that autophagy is the major degradational pathway following
unfolded protein response activation in neuronal cells, an
early event in AD brain, suggesting a connection between
its activation and the observed autophagic pathology [99].
Accordingly, an accumulation of autophagic vesicles in the
cortex of AD patients compared to nondemented ones has
been shown [98].Moreover, an increase of autophagic vesicles
containing mitochondria in pyramidal neurons from AD
patients has been found, suggesting a mitophagy alteration
[94, 100]. According to this, Parkin, one of the proteins
involved in the target of mitochondria to be degraded by
mitophagy, has been shown to be reduced in the cortex of
AD brains [101]. Additionally, autophagy alterations have
been described in AD brain and animal models. Beclin 1, a
protein that plays a key role in autophagy, has been shown to
be diminished in the affected brain regions in AD patients
early in the disease process [102]. In the same work, in
an APP transgenic mouse model, the downregulation or
overexpression of beclin1 increased or diminished, respec-
tively, the A𝛽 accumulation, extracellular A𝛽 deposition, and
neurodegeneration, highlighting the relevance of autophagy
in AD-related pathology. Moreover, a link between FAD
and autophagy has been recently indicated, showing that
autophagy requires functional Ps-1 for lysosomal maturation
and that is impaired by Alzheimer-related ps-1 mutations
[103]. Thus, ps-1 mutations could indirectly affect mitochon-
drial function by impairing its recycling by mitophagy.
On the other hand, autophagy has been proposed to play
an active role in AD pathogenesis. In this regard, autophagic
vesicles have been demonstrated to be an active compart-
ment for A𝛽 generation and their abnormal accumulation
in affected neurons of the AD brain contributes to A𝛽
deposition [104].
Due to the crucial role of autophagy in AD, the Moussa
group proposed the induction of autophagy by overexpres-
sion of Parkin as a therapeutic strategy. Parkin could ubiqui-
tinate and decrease intracellular A𝛽 levels and plaque depo-
sition by a synergistic activation of proteasomal degradation
[105] and Beclin1-dependent autophagic clearance [106].
Additionally, Parkin-induced autophagy facilitated clearance
of vesicles containing debris and defective mitochondria
counteracting oxidative stress and preventing mitochondrial
dysfunction [106]. Parkin reverses intracellular A𝛽 accumu-
lation and its negative effects on proteasome function [101].
Other strategies for the induction of autophagy as a ther-
apeutic strategy in AD have been tested in animal models for
the disease. With this aim several molecules have been tested
such as rapamycin [107, 108], cystatin B [109], trehalose [110],
scyllo-Inositol [111], and latrepirdine [112], although effects on
improving mitochondrial recycling were not studied in these
works.
6. Novel Models for the Study of AD
Hitherto, the majority of observations about mitochondrial
failure come from the study of animal models of familial
AD, patient-derived nonneuronal cells, and postmortem
analysis of the patient’s brain. As we have previously dis-
cussed, mitochondria are highly dynamic organelles which
coordinate a vast amount of cellular functions; therefore,
although the analysis of the brain can give us clues about
alterations in the amount of involved proteins and in the
structural changes by image analysis, for the proper study of
mitochondrial function the use of living cells is necessary.
In this direction, the use of patient-derived fibroblasts can
be very helpful but we should not forget that these are not
the cells that degenerate in the disease, so they might be
subject to some kind of compensatory mechanism, making
them very different from neurons. Additionally, fibroblast
environment, energy requirements, and protein expression
pattern and morphology are very different from those of
neurons, so the extrapolation of the results obtained in
this kind of cells should be taken cautiously. FAD animal
models or the expression of AD human mutations in human
neuroprecursor cells offers us the possibility of studying
mitochondrial function in a cellular model related to the
disease. However, we should take into consideration that
the majority of AD cases are sporadic or are not related to
any known mutation associated with the disease. For these
reasons, there is an increasing effort in generating neuronal
cells derived from SAD patients.
A revolutionary work in 2006 by Takahashi and Yam-
anaka demonstrated for the first time that adult differentiated
cells such as fibroblasts are able to be retrodifferentiated to
generate stem cells [113]. Four transcriptions factors, Oct3/4,
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Sox2, c-Myc, and Klf4, were enough to induce pluripotency
in primary fibroblast indicating that cell programming could
be reversed. This innovative concept opens the possibility
of generating neuronal cells from patient-derived fibroblasts
having a deep impact on the study of neurodegenerative
diseases. Noteworthy, Yamanaka obtained the Nobel Prize
in 2012 in recognition to his discovery. After this pioneer
work many efforts have been done to successfully reproduce
this result in human fibroblasts [114] as well as optimize the
protocol by changing the transcriptional factors [115], as well
as substituting them by small molecules [116–118] or miRNAs
[119–121] for transcription factors.
An increasing number of papers have come out in the
last few years using fibroblasts for the generation of induced
pluripotent stem cells (iPS), some of which are focused in
the generation of neurons from these iPS for the study
of Alzheimer disease [122, 123]. Using this approach of
generating neurons from presenilin-associated FAD patient’s
fibroblasts, increased A𝛽42 production and secretion was
found [122]. Similar studies using sporadic and APP dupli-
cation associated AD fibroblasts have also found an increase
in A𝛽40, phospho-Tau (Thr 231), or in active GSK3 (lacking
Ser9 phosphorylation) as well as the accumulation of early
endosomes [123].
More recently, direct conversion of fibroblast to func-
tional neurons (induced neurons, iN) by just three tran-
scription factors, Ascl1, Brn2 (also called Pou3f2), and Myt1l
has been described [124]. This was subsequently reproduced
by using human fibroblasts [125]. Also, microRNA-mediated
conversion of human fibroblasts to neurons has been indi-
cated, although its efficiency is increased by the addition of
transcription factors [126]. Additionally, a combination of
one microRNA and two transcription factors appears to be
sufficient to reprogram human fibroblasts to functional neu-
rons [127]. Other authors have reported the direct conversion
of fibroblasts to neural progenitor cells [128] or tripotent
neural precursor cells (iNSC) [129, 130] which have the
advantage of being expandable.
The conversion of human fibroblasts from Alzheimer
disease patients directly to functional neurons has been
reported [131].These reprogrammed neurons exhibit some of
the hallmarks of the brain of the patients such as an altered
processing of amyloid precursor protein and an increased
production of A𝛽.
Several works have pointed out that there are differences
in gene expression patterns between iPS, embryonic stem
cells, and somatic cells [132, 133]. These differences involve
reprogramming process-dependent genes and those retained
from somatic cells due to epigeneticmemory.This fact should
be taken into consideration to extrapolate the results obtained
using these models. However, to better understand the rele-
vance of these differences in the field of neurodegenerative
diseases it would be necessary to compare the gene expression
pattern of the reprogrammed cells with the somatic original
cell as well as neuronal tissue from the same patient.
Although an increasing amount of work now uses either
iPS, iN, or iNSC for modeling neurodegenerative diseases,
in the case of Alzheimer, no mitochondrial function studies
have been done so far in these models. Further efforts will
be necessary to improve the efficiency of these protocols to
increase neuron generation rate in order to perform this kind
of approach.
Mitochondrial function is essential for neuronal differ-
entiation and survival. Taking into consideration all the
mitochondrial alterations described for Alzheimer disease, it
is possible that the reprogramming of fibroblasts from AD
patients into neurons could be more difficult. It has been
described thatmtDNA integrity is essential formitochondrial
maturation during differentiation of neuronal stem cells
[134]; therefore, it is possible that lack of mtDNA integrity
due to oxidative damage of nucleic acids may impair the
reprogramming from fibroblasts to neurons. Also, a change
in protein levels, like DLP1, previously mentioned, or other
mitochondrial proteins such as prohibitin [135], could make
AD fibroblasts more vulnerable to mitochondrial damage
diminishing the efficiency of reprogramming. Therefore, the
study of mitochondria during the reprogramming process
might give important clues to understand not only the role
of mitochondria during neuronal differentiation but also the
relevance of AD-associatedmitochondrial dysfunction in the
neurodegeneration process.
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